Nebivolol induces distinct changes in profibrosis MicroRNA expression compared with atenolol, in salt-sensitive hypertensive rats

Hypertension

Volumn 61, Issue 5, 2013, Pages 1008-1013

  Ye, Hongmei ^a   Ling, Shukuan ^a,b   Castillo, Alexander C ^b   Thomas, Bejoy ^b   Long, Bo ^b   Qian, Jinqiao ^b,c   Perez Polo, Jose R ^b   Ye, Yumei ^b   Chen, Xiaoping ^a   Birnbaum, Yochai ^b,d  

^a Astronaut Research and Training Center of China   (China)

^b University of Texas Medical Branch School of Medicine   (United States)

^c KUNMING MEDICAL UNIVERSITY   (China)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

blocker; fibrosis; hypertension; microRNA; remodeling

Indexed keywords

ATENOLOL; COLLAGEN; MICRORNA; MICRORNA 133A; MICRORNA 27A; MICRORNA 29A; NEBIVOLOL; PROTEIN CDC42; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; COMPARATIVE STUDY; CONTROLLED STUDY; DAHL SALT SENSITIVE RAT; GENE EXPRESSION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART RATE; HIGH SODIUM INTAKE; HYPERTENSION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BENZOPYRANS; BLOOD PRESSURE; CDC42 GTP-BINDING PROTEIN; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ETHANOLAMINES; FIBROSIS; HYPERTENSION; IMMUNOGLOBULINS; MALE; MICRORNAS; MYOCARDIUM; PILOT PROJECTS; RATS; RATS, INBRED DAHL; RATS, SPRAGUE-DAWLEY;

EID: 84876672015     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.00892     Document Type: Article

References (30)

1. Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CP, Dupont AG, Van Nueten L, Wooding SJ, Ritter JM. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther. 1995;274:1067-1071.
2. Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocar-dial disease by stimulating MAP kinase signalling in fbroblasts. Nature. 2008;456:980-984.
3. Vinereanu D, Gherghinescu C, Ciobanu AO, Magda S, Niculescu N, Dulgheru R, Dragoi R, Lautaru A, Cinteza M, Fraser AG. Reversal of subclinical left ventricular dysfunction by antihypertensive treatment: a prospective trial of nebivolol against metoprolol. J Hypertens. 2011;29:809-817.
4. Divakaran V, Mann DL. The emerging role of microRNAs in cardiac remodeling and heart failure. Circ Res. 2008;103:1072-1083.
5. Cheng Y, Zhu P, Yang J, Liu X, Dong S, Wang X, Chun B, Zhuang J, Zhang C. Ischaemic preconditioning-regulated miR-21 protects heart against ischaemia/reperfusion injury via anti-apoptosis through its target PDCD4. Cardiovasc Res. 2010;87:431-439.
6. Boettger T, Braun T. A new level of complexity: the role of microRNAs in cardiovascular development. Circ Res. 2012;110:1000-1013.
7. Dockstader K, Nunley K, Karimpour-Fard A, Medway A, Nelson P, Port JD, Liggett SB, Bristow MR, Sucharov CC. Temporal analysis of mRNA and miRNA expression in transgenic mice overexpressing Arg-and Gly389 polymorphic variants of the β1-adrenergic receptor. Physiol Genomics. 2011;43:1294-1306.
8. Lu Y, Zhang Y, Shan H, Pan Z, Li X, Li B, Xu C, Zhang B, Zhang F, Dong D, Song W, Qiao G, Yang B. MicroRNA-1 downregulation by propranolol in a rat model of myocardial infarction: a new mechanism for ischaemic cardioprotection. Cardiovasc Res. 2009;84:434-441.
9. Zhu W, Yang L, Shan H, Zhang Y, Zhou R, Su Z, Du Z. MicroRNA expression analysis: clinical advantage of propranolol reveals key microRNAs in myocardial infarction. PLoS ONE. 2011;6:e14736.
10. Cheng Y, Ji R, Yue J, Yang J, Liu X, Chen H, Dean DB, Zhang C. MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy? Am J Pathol. 2007;170:1831-1840.
11. van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, Richardson JA, Olson EN. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA. 2006;103:18255-18260.
12. Kriegel AJ, Liu Y, Fang Y, Ding X, Liang M. The miR-29 family: genom-ics, cell biology, and relevance to renal and cardiovascular injury. Physiol Genomics. 2012;44:237-244.
13. Tatsuguchi M, Seok HY, Callis TE, Thomson JM, Chen JF, Newman M, Rojas M, Hammond SM, Wang DZ. Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. J Mol Cell Cardiol. 2007;42:1137-1141.
14. Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, van der Made I, Herias V, van Leeuwen RE, Schellings MW, Barenbrug P, Maessen JG, Heymans S, Pinto YM, Creemers EE. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res. 2009;104:170-178, 6p following 178.
15. Carè A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med. 2007;13:613-618.
16. Matkovich SJ, Wang W, Tu Y, Eschenbacher WH, Dorn LE, Condorelli G, Diwan A, Nerbonne JM, Dorn GW II. MicroRNA-133a protects against myocardial fbrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res. 2010;106:166-175.
17. Udvadia AJ, Rogers KT, Higgins PD, Murata Y, Martin KH, Humphrey PA, Horowitz JM. Sp-1 binds promoter elements regulated by the RB protein and Sp-1-mediated transcription is stimulated by RB coexpression. Proc Natl Acad Sci USA. 1993;90:3265-3269.
18. Bouwman P, Philipsen S. Regulation of the activity of Sp1-related transcription factors. Mol Cell Endocrinol. 2002;195:27-38.
19. Grohé C, Kahlert S, Löbbert K, Neyses L, van Eickels M, Stimpel M, Vetter H. Angiotensin converting enzyme inhibition modulates cardiac fbroblast growth. J Hypertens. 1998;16:377-384.
20. Azakie A, Fineman JR, He Y. Sp3 inhibits Sp1-mediated activation of the cardiac troponin T promoter and is downregulated during pathological cardiac hypertrophy in vivo. Am J Physiol Heart Circ Physiol. 2006;291:H600-H611.
21. Aragón JP, Condit ME, Bhushan S, Predmore BL, Patel SS, Grinsfelder DB, Gundewar S, Jha S, Calvert JW, Barouch LA, Lavu M, Wright HM, Lefer DJ. Beta3-adrenoreceptor stimulation ameliorates myocardial ischemia-reperfusion injury via endothelial nitric oxide syn-thase and neuronal nitric oxide synthase activation. J Am Coll Cardiol. 2011;58:2683-2691.
22. Ichihara S, Obata K, Yamada Y, Nagata K, Noda A, Ichihara G, Yamada A, Kato T, Izawa H, Murohara T, Yokota M. Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors. J Mol Cell Cardiol. 2006;41:318-329.
23. Cogan JG, Subramanian SV, Polikandriotis JA, Kelm RJ Jr, Strauch AR. Vascular smooth muscle alpha-actin gene transcription during myofbro-blast differentiation requires Sp1/3 protein binding proximal to the MCAT enhancer. J Biol Chem. 2002;277:36433-36442.
24. Clerk A, Sugden PH. Small guanine nucleotide-binding proteins and myo-cardial hypertrophy. Circ Res. 2000;86:1019-1023.
25. Kaibuchi K, Kuroda S, Amano M. Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells. Annu Rev Biochem. 1999;68:459-486.
26. Lengfeld J, Wang Q, Zohlman A, Salvarezza S, Morgan S, Ren J, Kato K, Rodriguez-Boulan E, Liu B. Protein kinase C δ regulates the release of collagen type I from vascular smooth muscle cells via regulation of Cdc42. Mol Biol Cell. 2012;23:1955-1963.
27. Nagai T, Tanaka-Ishikawa M, Aikawa R, Ishihara H, Zhu W, Yazaki Y, Nagai R, Komuro I. Cdc42 plays a critical role in assembly of sarco-mere units in series of cardiac myocytes. Biochem Biophys Res Commun. 2003;305:806-810.
28. Maillet M, Lynch JM, Sanna B, York AJ, Zheng Y, Molkentin JD. Cdc42 is an antihypertrophic molecular switch in the mouse heart. J Clin Invest. 2009;119:3079-3088.
29. Surviladze Z, Waller A, Strouse JJ, Bologa C, Ursu O, Salas V, Parkinson JF, Phillips GK, Romero E, Wandinger-Ness A, Sklar LA, Schroeder C, Simpson D, Noth J, Wang J, Golden J, Aube J. A potent and selective inhibitor of cdc42 gtpase. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010 Feb 27 [updated 2010 Dec 16]. 2010.
30. Maffei A, Di Pardo A, Carangi R, Carullo P, Poulet R, Gentile MT, Vecchione C, Lembo G. Nebivolol induces nitric oxide release in the heart through inducible nitric oxide synthase activation. Hypertension. 2007;50:652-656.